Home Clinical trials For patients Ovary IMGN853-0424

IMGN853-0424

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

Open
Trial drug
Mirvetuximab Soravtansine
Grade
High grade, Low grade, Other / unknown
Prior lines
1, 2, 3, 4
Histology
Serous, Mucinous Endometrioid Clear-cell
Platin
Platinum sensitive
Platinum resistant
Secondary platinum refractory
Phase
II

Treatment

The treatment in this study is Mirvetuximab Soravtansine.
Mirvetuximab Soravtansine will be administered intravenously every 3 weeks.
Protective eye drops will also be administered.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.